Original Research Article

Association Assessment of Peptidylarginine Deiminase Type 4 (PADI4) rs1748033 polymorphism and susceptibility to rheumatoid arthritis in Gorgan, Northeast of Iran

Aytekin Aghchelli¹, Yaghoub Yazdani²*, Hadi Bazzazi³, Mehrdad Aghaei⁴

¹Department of Biology, Gorgan Branch, Islamic Azad University, Gorgan, Iran ²Infectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran ³Department of Medical Laboratory Sciences, Gorgan Branch, Islamic Azad University, Gorgan, Iran ⁴Golestan Rheumatology Research Center (GRRC), Golestan University of Medical Sciences, Gorgan, Iran

ABSTRACT

Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease in which both genetic and environmental factors could be involved. Peptidyl arginine deiminase type IV (PADI4) is an enzyme responsible for the posttranslational conversion of arginine residues into citrulline. The association between PADI4 single nucleotide polymorphisms (SNPs) and RA susceptibility have been reported. Here, we aimed to assess the association of PADI4-104 (rs1748033) variant with the susceptibility to RA in an Iranian population in northeast of Iran. Materials and methods: A total of 130 RA patients and 128 age- and sex-matched healthy donors were recruited. The amplification-refractory mutation system with allele specific primers was used to detect PADI4-104 SNP. Disease activity was calculated using Disease Activity Scale 28a. SPSS 22.0 and SNPstat online software were used to analyze data using relevant statistical tests. Results: The CC genotype was more frequent in healthy subjects compared to RA patients. Setting the CC genotype as the reference, the TT genotype was significantly associated with increased risk of RA [OR = 2.11, 95% CI (1.45–3.07), P-value = 0.0001]. Moreover, no significant association was observed between genotypes and the disease activity score (P=0.154). Conclusions: The present study suggests that the PADI4-104 genetic variants are associated with RA susceptibility but not with the disease activity. While this is the first time to report such association in an Iranian population in northeast of Iran, further studies are required to confirm these findings.

KEYWORDS: Amplification-refractory mutation system; Peptidylarginine Deiminase Type 4; Rheumatoid arthritis; Single nucleotide polymorphism

*Correspondence: Yaghoub Yazdani, Address: Infectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran, Telephone: +98-1732425995, Email: yazdani@goums.ac.ir

INTRODUCTION

Rheumatoid arthritis (RA [MIM no. 180300]) is a multi-factorial, systemic and chronic inflammatory disease in which the immune response is dysregulated [1]. RA predominantly affects the synovial joints and may lead to progressive destruction of affected organs [2]. As a growing health burden that leads to limitation of daily activities, RA affects approximately up to 1% of the adult population worldwide [3]. Although the etiology of RA is not thoroughly elucidated, both genetic and environmental factors are thought to be involved in susceptibility to the disease [4, 5]. The genetic component may account for approximately 60% of RA pathogenesis [4]. Recent findings have represented growing evidence on heritability of risk alleles at a number of genetic loci, which may predispose individuals to RA [6]. Human leukocyte antigen (HLA) class II molecules and related genetic loci have been considered as the most powerful genetic factors associated with RA [7]. However, several genes outside the HLA region including cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) [8], PTN22 [9], STAT4 [10, 11] and peptidyl arginine deiminase type IV (PADI4) [12,13] have been proposed according to linkage-based approaches for assessment of genetic susceptibility and associations with RA. Peptidyl arginine deiminase type IV (PADI4) (NM_012387) is a member of the PADI gene family (located on human chromosome 1p36; a linkage region for RA), which encodes...
enzymes responsible for the posttranslational conversion of arginine residues into citrulline [12,14]. Autoantibodies directed against cyclic citrullinated peptides (CCPs) may result in breakdown of immunological tolerance due to the subsequent changes in their conformation and antigenicity, which play a crucial role in the RA pathogenesis [15]. PADI4 mRNA and protein is overexpressed in pathological synovial tissues and peripheral blood mononuclear cells (PBMCs) of RA patients [16,17]. Furthermore, several studies have addressed the association of PADI4 single nucleotide polymorphisms (SNPs) and functional variants with RA susceptibility [13, 18]. However, the results of such studies in various populations have been controversial. Considering the lack of sufficient data on this association in Iran, we aimed to assess the association of PADI4-104 (rs1748033) genetic variants with the susceptibility to RA in an Iranian population.

MATERIALS AND METHODS

Patients and controls
A total of 128 patients fulfilling the revised criteria of the American College of Rheumatology for RA were selected from the Rheumatology Research Center of Sayyad Shirazi educational hospital in Gorgan, Iran. The primary diagnosis and clinical manifestations were confirmed and Disease Activity Scale (DAS) 28a [19] was calculated by a rheumatologist. A total of 130 age- and sex-matched healthy subjects were also enrolled. Informed consent was obtained from all individuals. A volume of 5mL whole blood was taken from all participants. The samples were transferred to the laboratory and plasma was isolated immediately and stored at -80 ºC. Anti-CCP was measured by enzyme-linked immunosorbent assay (ELISA) using Human CCP ELISA Kits (Mybioscource, SD, USA). PBMCs were separated using Ficoll-Paque (Baharafshan, Tehran, Iran) gradient centrifugation as described previously [20]. Clinical and laboratory data were also obtained using filed documents and latest laboratory test results.

DNA extraction and genotyping
DNA was extracted from PBMCs using a genomic DNA isolation kit (Dena Zist, Iran) and kept at -20 ºC until use. The amplification-refractory mutation system with allele specific primers (Table 1) was used to amplify the polymorphic region and to detect rs1748033 SNP (C/T) in the PADI4 gene. Polymerase chain reaction (PCR) was performed in a 25 mL reaction solution containing 50 ng of template DNA, 10X PCR buffer (GeNet Bio, Korea), 2 mM MgCl2, 0.5 mM of each primer and 1.5 U Taq polymerase (GeNet Bio, Korea). Amplification conditions were as follows: initial denaturation at 95 ºC for 5 minutes, 35 cycles of denaturation at 95 ºC for 25 seconds, annealing at 58 ºC for 30 seconds, extension at 72 ºC for 30 seconds and final extension at 72 ºC for 10 minutes. PCR products were electrophoresed on 1.5% agarose gel and presence of a 190 bp band represented both alleles (C and T). A 422-bp fragment was used as internal control for the PCR experiment.

Table1. List of primers used in the amplification-refractory mutation system PCR for detection of rs1748033 SNP (C/T) in the PADI4 gene

| Name     | Sequence (5’>3’)                  | Value                        |
|----------|-----------------------------------|------------------------------|
| PADI4-104F | GAGGGATGTCTTTGACAACCTGTGT         | Generic forward              |
| PADI4-104T | GGGTGATGTCTTGCGCACA             | T allele                     |
| PADI4-104C | GGGTGATGTCTCCGGCACTG            | C allele                     |
| hGH422-F | TTCCCAACCATTCCCTTA               | Internal control F           |
| hGH422-R | GGATTCTCTTGTTGTTTTC             | Internal control R           |

Statistical analysis
The Hardy-Weinberg equilibrium was checked by Pearson’s goodness of fit test. SPSS 22.0 (SPSS, Chicago, USA) and SNPstat online software (https://www.snpstats.net/start.htm) were used for statistical analysis of data. Odds ratio (OR) and 95% confidence interval (CI) were determined to evaluate case-control study associations. The Fisher’s exact test was used to compare genotype frequencies between groups. One-way analysis of variance (ANOVA) with Tukey’s post hoc test or nonparametric Kruskal-Wallis with Dunn-Bonferroni post hoc test was used to compare means of multiple samples. P-values less than 0.05 were considered as statistically significant.

RESULTS

PADI4-104 alleles and genotypes are associated with the increased risk of RA

The distribution of genotypes and alleles under different inheritance models (codominant, dominant, recessive and over-dominant) in RA patients and normal subjects were in the Hardy–Weinberg equilibrium. Comparison of the PADI4-104 (C/T) genotypes showed that the CC genotype was more frequent in healthy subjects. Setting the CC genotype as the reference, the TT genotype was significantly associated with increased risk of RA under co-dominant model [OR = 2.11, 95% CI (1.45–3.07), P-value = 0.0001] after adjusting for sex and age. These findings were confirmed under dominant [OR = 2.20, 95% CI (1.34–2.63), P-value = 0.0017] and recessive [OR = 4.48, 95% CI (1.87–10.74), P-value = 0.0001] models. Moreover, comparison of allele frequencies in patients and healthy donors suggested a significant association between T allele and RA susceptibility [OR = 2.11, 95% CI (1.45–3.07), P-value = 0.0001] (Table 2).

| Genotypes and alleles | Healthy subjects (n=130) | RA patients (n=128) | OR (95% CI) | P-value |
|-----------------------|--------------------------|--------------------|-------------|---------|
|                       | Number (%)              | Number (%)         |             |         |
| rs1748033             |                          |                    |             |         |
| C                     | 347 (67%)                | 150 (59%)          | Reference   |         |
| T                     | 169 (33%)                | 106 (41%)          | 2.11 (1.45-3.07) | 0.0001 |
| Co-dominant model     |                          |                    |             |         |
| CC                    | 74 (56.9%)               | 48 (37.5%)         | Reference   |         |
| CT                    | 49 (37.7%)               | 54 (42.2%)         | 1.70 (1.00-2.89) |         |
| TT                    | 7 (5.4%)                 | 26 (20.3%)         | 5.73 (2.30-14.23) | 0.0001 |
| Dominant model        |                          |                    |             |         |
| CC                    | 74 (56.9%)               | 48 (37.5%)         | Reference   |         |
| CT+TT                 | 56 (43.1%)               | 80 (62.5%)         | 2.20 (1.34-3.63) | 0.0017 |
| Recessive model       |                          |                    |             |         |
| CC+CT                 | 123 (94.6%)              | 102 (79.7%)        | Reference   |         |
| TT                    | 7 (5.4%)                 | 26 (20.3%)         | 4.48 (1.87-10.74) | 0.0001 |
| Over-dominant model   |                          |                    |             |         |
| CC+TT                 | 81 (62.3%)               | 74 (57.8%)         | Reference   |         |
| CT                    | 49 (37.7%)               | 54 (42.2%)         | 1.21 (0.73-1.99) | 0.46   |
| X² HWE*               | 2.18                     | 0.91               |             |         |
| (P-value)             | 0.13                     | (0.76)             |             |         |

*P-values lower than 0.05 are considered as statistically significant. Significant associations are shown in Bold.

Sex and age adjustment was performed to standardize the risk assessment.
PADI4-104 genotypes are not associated with disease activity score
We evaluated the association of PADI4-104 genotypes with the clinical and laboratory characteristics of RA patients. Regarding the DAS-28a, no significant difference was observed between the genotypes (P=0.154).

Erythrocyte sedimentation rate was significantly higher among RA patients with the TT genotype compared to other genotypes (P=0.029). No other significant association was observed regarding the clinical and laboratory characteristics of RA patients and PADI4-104 genotypes (Table 3).

![Table3. Clinical and laboratory characteristics of RA patients regarding the PADI4-104 genotypes](image)

| Characteristics and genotypes (N=130) | CC       | TT       | CT       | P-value |
|--------------------------------------|----------|----------|----------|---------|
| Age                                 | 49.87±2.36 | 45.58±3.42 | 51.69±1.99 | 0.287   |
| DAS28a                              | 3.45±0.31  | 2.71±0.39  | 3.65±0.33  | 0.154   |
| Erythrocyte sedimentation rate       | 20.12±2.67* | 35.11±5.03* | 28.11±4.01 | 0.029   |
| Age of onset                         | 44.26±3.31  | 38.75±2.98  | 42.31±2.89  | 0.580   |
| Anti-CCP                             | Positive  | 52.9%     | 23.5%     | 23.5%   | 0.416   |
|                                      | Negative  | 39.5%     | 18.4%     | 42.1%   |
| Family history                       | Yes       | 31%       | 27.6%     | 41.4%   | 0.129   |
|                                      | No        | 50%       | 11.4%     | 38.65   |

Data are presented as mean ± standard error for continuous variables and as percentages of positive patients (%) for categorical variables. Significant associations are shown in bold. * P-value <0.05

DISCUSSION
Although the etiology of RA is not thoroughly understood, both genetic and environmental factors could be involved in its initiation and progression [4, 5]. Several risk alleles at a number of genetic loci have been associated with predisposition to RA including genetic variants in HLA II [7], CTLA4 [8], PTN22 [9], STAT4 [10, 11] and PADI4 [13]. The PADI4 gene encodes an enzyme responsible for the posttranslational conversion of arginine residues into citrulline [12, 14], which plays a crucial role in the RA pathogenesis [15-17]. Several studies have addressed the association between PADI4 genetic variants and RA susceptibility [13, 18]. However, no study has yet evaluated the relationship between PADI4 SNPs and RA susceptibility in Iran. Therefore, we assessed the association of PADI4-104 (rs1748033) genetic variants with the susceptibility to RA in an Iranian population using different inheritance models.

A study by Suzuki et al. in Japan was the first to report the association of the PADI4 gene polymorphisms including PADI4-104 and increased risk of RA [13]. Other studies evaluated the association of PADI4-104 genetic variants with RA in Korean [21] and Japanese [18, 22] populations. No significant association was observed between PADI4-104 genetic variants and RA in German [23], Spanish [24] and White British [24] populations. In a recent meta-analysis of 16 studies including 7551 cases and 6394 controls, a significant association between PADI4-104 genetic variants and RA was observed for Asians but not for Europeans [25]. Du et al. reported that the PADI4-104 polymorphism was significantly associated with RA susceptibility in a Chinese Han population [26]. Another meta-analysis performed by Lee et al. revealed that the PADI4-104 was a significant risk factor for Asian RA patients [27]. The TT genotype was associated with the increased risk of RA development in the mentioned studies. Similarly, we revealed that the CC genotype was more frequent in healthy subjects compared to RA patients. Setting the CC
genotype as the reference, the TT genotype was found to be significantly associated with increased risk of RA. In India, Panati et al. showed that CT-CC genotype of PADI4-104 SNP was associated with decreased risk of RA and reported C allele as the risk allele [28], which is in contrast to our findings. However, most investigations on Caucasians revealed no association between RA susceptibility and PADI4 polymorphisms [21, 24]. The inconsistency of findings in various studies might be due to the heterogeneity of populations and complicating environmental factors.

There are not enough data on the association of the PADI4 gene polymorphisms with RA susceptibility among the Iranian population [29, 30]. Thus far, only one study in Zahedan (southeast of Iran) has investigated the PADI4-104 genetic variants among Iranian RA patients [30]. In line with our findings, the mentioned study stated that the PADI4-104 variant increased the risk of RA in codominant and dominant inheritance models. Moreover, the T allele was reported to increase the risk of RA compared to the C allele, which is consistent with our findings.

CONCLUSION
Our findings reveal that the PADI4-104 genetic variants could be associated with the susceptibility to RA but not with the disease activity in Iranians in Gorgan, northeast of Iran. Further clinical and molecular studies are required to better elucidate the role of the PADI4 gene polymorphisms in the RA pathogenesis.

ACKNOWLEDGMENTS
This article was derived from a thesis for completion of an MSc degree in Biology at Islamic Azad University, Gorgan Branch, Gorgan, Iran.

REFERENCES
1. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. The Lancet. 2017;389(10086):2328-37.

2. Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis & rheumatology. 2016;68(1):1-26.

3. Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Annals of the rheumatic diseases. 2014.

4. Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506(7488):376.

5. Catrina AI, Deane KD, Scher JU. Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis. Rheumatology. 2014;55(3):391-402.

6. Nelson JL, Lambert NC. Rheumatoid arthritis: Forward and reverse inheritance—the yin and the yang. Nature Reviews Rheumatology. 2017;13(7):396.

7. van Heemst J, Huizinga TJ, van der Woude D, Toes RE. Fine-mapping the human leukocyte antigen locus in rheumatoid arthritis and other rheumatic diseases: identifying causal amino acid variants? Current opinion in rheumatology. 2015;27(3):256-61.

8. Lei C, Dongqing Z, Yeqing S, Oaks MK, Lishan C, Jianzhong J, et al. Association of the CTLA-4 gene with rheumatoid arthritis in Chinese Han population. European journal of human genetics. 2005;13(7):823.

9. Karlson EW, Chibnik LB, Cui J, Plenge RM, Glass RJ, Maher NE, et al. Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study. Annals of the rheumatic diseases. 2008;67(3):358-63.

10. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. New England Journal of Medicine. 2007;357(10):977-86.

11. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nature genetics. 2010;42(6):508.

12. Bang S-Y, Han T-U, Choi C-B, Sung Y-K, Bae S-C, Kang C. Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study. Arthritis research & therapy. 2010;12(3):R115.
13. Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nature genetics. 2003;34(4):395.

14. Harris ML, Darrah E, Lam GK, Bartlett SJ, Giles JT, Grant AV, et al. Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis & Rheumatology. 2008;58(7):1958-67.

15. Van Venrooij WJ, Van Beers JJ, Pruijn GJ. Anti-CCP antibodies: the past, the present and the future. Nature Reviews Rheumatology. 2011;7(7):391.

16. Vossenaar ER, Radstake TR, van der Heijden A, van Mansum MA, Dieteren C, de Rooij D-J, et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Annals of the rheumatic diseases. 2004;63(4):373-81.

17. Foulquier C, Sebbag M, Clavel C, Chapuy-Regaud S, Al Badine R, Méchin MC, et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis & Rheumatology. 2007;56(11):3541-53.

18. Iwamoto T, Ikari K, Nakamura T, Kuwahara M, Toyama Y, Tomatsu T, et al. Association between PADI4 and rheumatoid arthritis: a meta-analysis. Rheumatology. 2006;45(7):804-7.

19. Fransen J, Stucki G, van Riel PL. Rheumatoid arthritis measures: Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis Care & Research. 2003;49(S5).

20. Mohammadi S, Sedighi S, Memarian A, Yazdani Y. Overexpression of interferon-γ and indoleamine 2, 3-dioxygenase in systemic lupus erythematosus: relationship with the disease activity. Laboratoriums Medizin. 2017;41(1):41-7.

21. Barton A, Bowes J, Eyre S, Spreckley K, Hinks A, John S, et al. A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population. Arthritis & Rheumatology. 2004;50(4):1117-21.

22. Ikari K, Kuwahara M, Nakamura T, Momohara S, Hara M, Yamanaka H, et al. Association between PADI4 and rheumatoid arthritis: a replication study. Arthritis & Rheumatology. 2005;52(10):3054-7.

23. Hoppe B, Häupl T, Gruber R, Kiesewetter H, Burmester GR, Salama A, et al. Detailed analysis of the variability of peptidylarginine deiminase type 4 in German patients with rheumatoid arthritis: a case–control study. Arthritis research & therapy. 2006;8(2):R34.

24. Martinez A, Valdivia A, Pascual-Salcedo D, Lamas JR, Fernandez-Arquer M, Balsa A, et al. PADI4 polymorphisms are not associated with rheumatoid arthritis in the Spanish population. Rheumatology. 2005;44(10):1263-6.

25. Hou S, Gao G-p, Zhang X-j, Sun L, Peng W-j, Wang H-f, et al. PADI4 polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis. Modern rheumatology. 2013;23(1):50-60.

26. Du Y, Liu X, Guo J, Li R, Zhao Y, Li M, et al. Association between PADI4 gene polymorphisms and anti-cyclic citrullinated peptide antibody positive rheumatoid arthritis in a large Chinese Han cohort. Clinical and experimental rheumatology. 2014;32(3):377-82.

27. Lee YH, Bae S-C. Association between susceptibility to rheumatoid arthritis and PADI4 polymorphisms: a meta-analysis. Clinical rheumatology. 2016;35(4):961-71.

28. Panati K, Pal S, Reddy VD. Association of single nucleotide polymorphisms (SNPs) of PADI4 gene with rheumatoid arthritis (RA) in Indian population. Genes & genetic systems. 2012;87(3):191-6.

29. Shamsian E, Azarian M, Akhlaghi M, Samaei M, Jamshidi AR, Assar S, et al. PADI4 Polymorphisms in Iranian Patients with Rheumatoid Arthritis. Acta reumalogica portuguesa. 2016;41(4):338-43.

30. Hashemi M, Zakeri Z, Taheri H, Bahari G, Taheer M. Association between peptidylarginine deiminase type 4 rs1748033 polymorphism and susceptibility to rheumatoid arthritis in Zahedan, Southeast Iran. Iranian Journal of Allergy, Asthma and Immunology. 2015;14(3):255-60.